CLINICAL / SCIENTIFIC PRESENTATION AND PUBLICATION HIGHLIGHTS
The information contained in each post on this page was factually accurate on the date it was issued and posted.
10th Annual World ADC London 2020 – PowerPoint Presentation
To download the presentation, CLICK HERE
Sutro Biopharma to Present Innovative Cancer Therapy Approach Using Precise Tumor Targeted Immunostimulants at World ADC London
SOUTH SAN FRANCISCO, Calif., March. 4, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Cell Free Systems Conference 2019 – Cell-Free Protein Synthesis Scale-Up and GMP Production of Protein Biotherapeutics for Clinical Trials – Poster
Cell Free Systems Conference 2019 - Poster Please click the link to enlarge image, Cell Free Systems Conference 2019
Cell Free Systems Conference 2019 – Antibody Reduction Mitigation during Harvest from Cell-Free Protein Synthesis – Poster
Cell Free Systems Conference 2019 - Poster Antibody Reduction Mitigation during Harvest from Cell-Free Protein Synthesis. Please click the link to enlarge image, Cell Free Systems Conference 2019 Poster
American Society of Hematology Conference 2019 – STRO-001 – Abstract
Preliminary Results of a Phase 1 Dose Escalation Study of The First-In-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, In Patients With Advanced B-Cell Malignancies. Nirav N. Shah, Amrita Y. Krishnan, Nina D. Shah, John M. Burke, Jason M. Melear, Alexander I....
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – PowerPoint Presentation
To download, Click Here
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – Poster
Antitumor activity of STRO-002, a novel anti-folate receptor -⍺ (FolR⍺) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary Phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC) Please Click the Link, AACR...
Sutro Biopharma to Present at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer - Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer...
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – STRO-002 – Abstract
Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary Phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC) Denise Uyar, 1 Russell J...
Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held Oct. 26-30, 2019, in Boston....
